Schering-Plough Reports Financial Results for 2009 Seco...(h and development 906 ...)

Date:7/21/2009

h and development 906 (2) - - 904 Other expense/(income), net 134 - - - 134 Special and acquisition-related charges 94 - (94) - - Equity income (493) - - 64 (429) ----- - - -- ----- Income before income taxes 502 357 94 (64) 889 Income tax expense/(benefit) 40 (73) (7) - 120 -- ---- --- - --- Net income $462 $284 $87 $(64) $769 ---- ---- === ---- ---- Preferred stock dividends 38 - - - 38 -- - - - -- Net income available to common shareholders $424 $284 $87 $(64) $731 ==== ==== === ==== ==== Diluted earnings per common share $0.26 $0.45 ===== ===== Average shares outstanding common and participating - diluted 1,632 1,632 (1) "As Reconciled" to exclude purchase accounting adjustments, special and acquisition-related items and other specified items.

    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to
'/>"/>
SOURCE  Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma